- Advertisement -
Shares in Australian biotherapeutics giant CSL Ltd (ASX: CSL) slumped to a seven-year low this morning after CEO Paul McKenzie slashed growth forecasts for the company in FY26, largely due to a sharp decline in influenza vaccination rates in the US.
The shares hit a low of $176.01 – down almost…
Click here to view the original article.
